GHK-Cu dosage and evidence

What is GHK-Cu?

How does GHK-Cu work?

It carries copper into cells and turns on genes used in repair. That helps skin cells make collagen and the other building blocks that heal wounds.

What have studies in people found about GHK-Cu?

GHK-Cu has been used on more than 20,000 people in published studies. The biggest are hair clinics in Japan (18,918 men) and India (1,000 people), where scalp injections that included copper peptide were followed by less hair loss and happy patients, though those people were getting other hair treatments at the same time. On its own, a GHK-Cu gel helped diabetic foot ulcers close almost completely and cut infections. Two smaller studies, on leg ulcers and on skin after laser treatment, saw no visible difference. Users online report better results for skin than for hair.

• Hair clinic, Japan, 2011 to 2017, 18,918 men: a monthly scalp injection that included copper peptide, alongside finasteride and minoxidil, for six months or more. Every man's photos improved, 96% were satisfied at six months and 80% at a year, and about 4 in 100 had minor pain or bleeding at the needle. Because the men were also on the two standard hair-loss drugs, the copper peptide can't take the credit alone.
• Hair clinic, India, 2018, 1,000 men and women: scalp injections every three weeks, eight times, of a mix of copper peptide, growth factors and thymosin beta-4. 83% shed less hair, hair counts were still up at one year, and 75% felt it was helping. The result belongs to the whole mix.
• Diabetic foot ulcers, USA, 1994: a GHK-Cu gel every day alongside normal wound care. Ulcers on the sole closed 98.5% of the way, against 61% with the same gel minus the peptide, and infections fell from 34% to 7%. The study summary does not say how many people took part. This is the clearest result for copper peptide on its own.
• Leg ulcers from poor circulation, USA, 1992, 86 people: a copper peptide cream healed no better than a plain cream with nothing in it. An ordinary antibacterial cream beat both.
• Dandruff, India, 2024: a scalp scrub and a serum with copper peptide and four other active ingredients, for 15 days. Flaking dropped 61% and the scalp held more moisture. One author works for the maker.
• After laser skin treatment, USA, 2006, 13 people: aftercare creams with or without copper peptide for 12 weeks. Redness faded and wrinkles improved the same either way, but the people using copper peptide rated their skin better.
• A new wound-healing study of GHK-Cu gel in about 60 healthy adults (NCT07437586) started in February 2026 and is due to finish in early 2027.
• Injecting it: no published study has injected GHK-Cu by itself into people. FDA listed injectable GHK-Cu on its April 2026 safety page, saying there is little human data on its safety when injected.

What this does not tell you: The best records are clinic reports and user reports, because no company can patent GHK and so no company pays for big studies. The biggest hair results came with other treatments in the mix. Copper peptide on its own has one strong wound result and two small studies that saw no difference. Very little of it soaks through unbroken skin without help such as microneedling.

What do people who took GHK-Cu report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Split use. People apply it topically for skin and scalp, and inject it much less often. Topical is described by most as the sensible route, commonly mixed into water and sprayed or applied to scalp and face.
• Injecting it under the skin is described as genuinely unpleasant, with the injection site turning blue for two to three days and the injection itself reported as painful. That is the most consistent negative in the whole discussion and it is a reason people give for switching to topical.
• For hair, the repeated pattern is that nothing visible happens in the first four weeks and that people who report satisfaction are those who ran it six months alongside minoxidil and microneedling. Almost nobody reports it working alone.
• The most common realistic framing, stated by more experienced posters correcting newcomers, is that it does nothing for follicles that are fully dormant and scarred, and that whatever effect exists is on follicles still producing something. Expectation management is a recurring theme.
• Skin results are reported more favourably and more consistently than hair results, by the same people, which is worth noting given the hair claims are what most vendors lead with. Reports of reversed greying circulate but are individual accounts rather than a pattern.
• Side effect reports beyond the injection site are sparse, and discussion generally treats it as low risk. That is an absence of complaints in a self-selected group rather than a safety finding.

Sources: Threads on ExcelMale, LongeCity and Bluelight, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people1994
  Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper

  A GHK-Cu gel helped diabetic foot ulcers close. People used it every day alongside normal wound care, and their ulcers healed far better than with the same gel minus the peptide. The study summary does not say how many people took part.

  People with diabetes and foot ulcers at several US clinics, gel used daily alongside normal wound care. Ulcers on the sole closed 98.5% of the way, against 60.8% with the same gel minus the peptide. Larger ulcers closed 89.2%, against getting slightly bigger without it. Infections were 7% against 34%. Number of people not stated in the summary.

  PMID 17147644 Wound Repair and Regeneration
• Study in people1992
  A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

  The copper peptide cream did no better than a cream with nothing in it. 86 people with leg ulcers were sorted at random into three groups: copper peptide cream, the same cream without it, or a silver antibacterial cream. The people judging the ulcers did not know who got what. Only the silver cream shrank ulcers. This is the largest random test a copper peptide has ever been given, and it came out level with the dummy.

  86 evaluable patients randomized among 1% silver sulfadiazine cream, a 0.4% biologically active tripeptide copper complex cream and an inert vehicle placebo. Silver sulfadiazine statistically reduced ulcer size compared with the other two; there was no difference between the copper peptide cream and the placebo.

  PMID 1495150 Journal of Vascular Surgery
• Study in people2006
  Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

  Nothing an outside observer could measure got better. 13 patients had laser resurfacing around the mouth, then were assigned at random to a skincare routine with or without GHK-Cu. Judges who did not know which patient got which, plus computer image analysis, found no difference in redness, wrinkles or overall skin quality. The only thing that favoured the copper peptide was the patients' own satisfaction rating. Thirteen people is a very small test.

  13 patients randomized after circumoral CO2 laser resurfacing to a skincare regimen with or without GHK-Cu. Computer analysis and blinded evaluators found no significant difference in erythema resolution, wrinkles or overall skin quality. Only the patients' own questionnaire favoured GHK-Cu, at P = 0.04.

  PMID 16847171 Archives of Facial Plastic Surgery
• Study in people2024
  An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults

  The scalp flaking improved, and nothing here can tell you the copper peptide did it. Everyone in this study got the same two products, and there was no group that went without. The regimen carried five active ingredients across a scrub and a serum. Flaking scores, hair density and hair thickness all improved over two weeks. With nothing to compare against and five ingredients in the bottle, the copper peptide cannot be credited with any of it.

  Open label, single centre, single arm study of a two product regimen with five actives. Adherent Scalp Flaking Score improved 61.24% by day 15, hair density 12.48% and hair thickness 25.36%. No control arm and no way to attribute any result to the copper peptide.

  This study gave people a scalp scrub and serum with five active ingredients, one of them copper peptide, not GHK-Cu. It is here because it belongs on the record, and it is excluded from every count on this page.

  PMID 39449909 Cureus
• Study in people2018
  Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study

  Most people shed less hair after scalp injections of a mix that included copper peptide. The mix also held growth factors and thymosin beta-4, so the result belongs to the whole mix.

  Indian hair clinic, 1000 patients given scalp injections every 3 weeks, 8 times, of a mix of four growth factors, thymosin beta-4 and copper peptide. 83% shed less hair, hair counts were still up at 1 year, 75% felt it helped, and it was well tolerated.

  This study gave people a mix of growth factors, thymosin beta-4 and copper peptide, not GHK-Cu. It is here because it belongs on the record, and it is excluded from every count on this page.

  PMID 29482481 Journal of Cosmetic and Laser Therapy
• Study in people2018
  Androgenetic Alopecia Treatment in Asian Men

  A Japanese clinic treated 18,918 men with a monthly scalp injection that included copper peptide, and nearly all were happy with the result. They were also taking finasteride and minoxidil, the two standard hair-loss drugs.

  Japanese hair clinic, 2011 to 2017, 18,918 men on finasteride, minoxidil and a monthly scalp injection of a mix including copper peptide, for 6 months or more. Every man's photos improved; 96% were satisfied at 6 months and 80% at a year. Minor problems in 802 (4.2%), mostly pain or light bleeding at the needle.

  This study gave people finasteride and minoxidil plus an injected mix that includes copper peptide, not GHK-Cu. It is here because it belongs on the record, and it is excluded from every count on this page.

  PMID 30057663 Journal of Clinical and Aesthetic Dermatology
• Study in people2026
  Topical GHK-Cu Gel for Acute Skin Wound Healing

  This is the first trial built to ask whether GHK-Cu heals a wound, and it has reported nothing yet. Researchers plan to give about 60 healthy adults two small punch wounds, treating one with a GHK-Cu gel and the other with the same gel without it. Nobody involved will know which wound got which. It began recruiting in February 2026 and is expected to finish in early 2027. Until then there is no result to read.

  Phase 2, randomized, double-blind, vehicle-controlled, split-wound study of topical GHK-Cu gel on standardized punch-biopsy wounds in an estimated 60 healthy adults. Recruiting since 2 February 2026, primary completion estimated 14 February 2027. The only registered trial of GHK-Cu as a drug.

  NCT07437586 ClinicalTrials.gov, Hudson Biotech
• Review of studies2015
  GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

  A review of the research. GHK is in your blood and drops as you age. With copper attached, it helped skin make collagen and sped up wound healing in animals. Cosmetic studies reported firmer skin and fewer wrinkles.

  GHK is present in plasma and declines with age; as a copper complex it stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinases and accelerates wound healing in animal models, with cosmetic studies reporting firmer skin and fewer wrinkles.

  PMID 26236730 BioMed Research International
• Review of studies2026
  The Regenerative Potential of GHK-Cu in Aesthetic Medicine

  A review went looking for every study of GHK-Cu in aesthetic medicine and found almost nothing done in people. The authors searched three medical databases up to March 2026. They kept 20 studies. 18 of those were done in cells or animals, and only two split people into groups by chance. They call the human evidence limited, with few well designed trials and methods that vary from study to study.

  Systematic review to March 2026 across PubMed, Embase and Cochrane CENTRAL. 20 studies were included, 18 preclinical and 2 randomized controlled trials, and the authors describe the clinical evidence as limited by methodological variability and few well designed trials.

  PMID 42619529 Aesthetic Surgery Journal
• Review of studies2026
  Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

  This is a regulator's safety notice, not a study. FDA lists GHK-Cu among substances that carry risk when they are compounded for injection. It says there is little human data to judge safety by, and flags the chance that the peptide clumps or carries impurities the immune system reacts to. The page records a concern. It is not a finding that injected GHK-Cu is harmful, and it is not a finding that it works.

  FDA lists GHK-Cu for injectable routes of administration, citing risk of immunogenicity from aggregation and peptide-related impurities, and states there are limited data in humans to inform safety-related considerations. Updated 22 April 2026.

  Source U.S. Food and Drug Administration
• Animal study2000
  Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+)

  In rats. Repeated GHK-Cu shots into small wound chambers grew more wound tissue and more collagen.

  Repeated GHK-Cu injections into rat wound chambers increased wound tissue, type I collagen and glycosaminoglycan production.

  PMID 11121126 Journal of Investigative Dermatology
• Lab (cells in a dish)1988
  Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+

  In a dish. GHK-Cu made skin cells produce more collagen, even at tiny amounts.

  GHK-Cu stimulated fibroblast collagen synthesis from picomolar concentrations, maximal at 1 nM, independent of cell number.

  PMID 3169264 FEBS Letters
• Lab (cells in a dish)1973
  Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver

  This is where the copper peptide story starts, in a dish. GHK was pulled out of human blood in 1973 and shown to keep liver cells alive longer in culture. Nobody was given anything. Because the molecule has been public since then, no company can own it, and no company has had a reason to pay for a proper trial. That is why the market grew on skincare instead of evidence.

  The original isolation of GHK from human serum by Pickart and Thaler. The molecule has been in the public literature since 1973, which is why no company has ever been able to own it and why the copper peptide market was built on cosmetics rather than on trials.

  PMID 4349963 Nature: New Biology